Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Outlook 2023: The Pharma Rollercoaster Shows No Signs Of Slowing Down

Dec 12 2022

• By Jo Shorthouse

Rollercoaster — • Source: Shutterstock

Related Content

The Busiest Dealmakers Of 2022

Dec 01 2022

Cancer Drugs And Medicare: Range Of Impacts Expected From IRA Price Reforms

Nov 09 2022

Medicare Price ‘Negotiation’ Process Gets Broad Brush Treatment In New Law

Aug 16 2022

The Next Big Patent Cliff Is Coming, And Time Is Running Out To Pad The Fall

Apr 04 2022

Finance Watch: With Limited Fundraising Options, Biotechs Restructure To Extend Cash Runways

Oct 19 2022

Pfizer Leads Big Pharma M&A In 2022 – But Is There More To Come?

Oct 12 2022

After Cutting Back And Clinging On, Will Biotech Bounce Back In 2023?

Nov 16 2022

Finance Watch: Acrivon Adjusts Expectations To Launch $99.4m IPO

Nov 16 2022

IPO Outlook: 2021 Saw Record Numbers But Poor Returns; 2022 Looks Muted

Jan 07 2022

Related Companies

Bristol Myers Squibb Company

Novartis AG

Celgene Corporation

AbbVie Inc.

Pfizer Inc.

Merck & Co., Inc.

Arena Pharmaceuticals, Inc.

Biohaven Pharmaceutical Holding Company Ltd.

ReViral Ltd.

Johnson & Johnson

Mereo BioPharma Group plc

Genetix Biotherapeutics

BioMarin Pharmaceutical Inc.

Orchard Therapeutics Limited

Vertex Pharmaceuticals Incorporated

CRISPR Therapeutics AG

Insmed Incorporated

Acrivon Therapeutics, Inc.

Additional Topics

Commercial Growth Business Strategies Deals Financing Gene Therapy M & A Pricing Debate Politics Outlook 2023 BioPharmaceutical

More from Outlook Archive

More from Outlook 2024

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window